Managed Healthcare Executive August 25, 2023
Sandoz’s Tyruko, the first biosimilar to Biogen’s Tysabri, is expected to be available as soon as possible. Pricing has not yet been made available.
The FDA has approved Sandoz’s Tyruko (natalizumab-sztn), the first biosimilar to Biogen’s Tysabri (natalizumab) injection to treat adults with relapsing forms of multiple sclerosis (MS). Developed by Polpharma Biologics, Tyruko, like Tysabri, is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn’s disease.
Multiple sclerosis is an autoimmune disease of the central nervous system. It is among the most common causes neurological disability in young adults and occurs more frequently in women than men. Most people with MS experience periods of new symptoms or relapses that...
Today's Sponsors
Today's Sponsor